Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
MENLO PARK, Calif., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the following investor conferences:
- Piper Jaffray 27th Annual Healthcare Conference in New York at 8:30 a.m. ET on Wednesday, December 2, 2015. The live and archived webcast will be available at http://edge.media-server.com/m/p/u46tsbd2.
- Oppenheimer 26th Annual Healthcare Conference in New York at 9:45 a.m. ET on December 9, 2015. The live and archived webcast will be available at http://www.veracast.com/webcasts/opco/healthcare2015/84203554236.cfm.
Geron management will also be hosting an analyst and investor meeting to discuss imetelstat data presented at the 57th American Society of Hematology (ASH) Annual Meeting:
- The meeting will be held at 7:30 p.m. ET on Saturday, December 5, 2015. The live and archived webcast will be available at http://edge.media-server.com/m/p/o3ovz2db/lan/en.
Following the live presentations, the webcasts will be archived and available for replay for a period of 30 days.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
CONTACT: Anna Krassowska, Ph.D. Investor and Media Relations 650-473-7765 [email protected] [email protected]
